SYRE Q2 2017 Earnings — Spyre Therapeutics, Inc. Revenue & Financial Results | Market Cap Arena

SYRESpyre Therapeutics, Inc.

$3B

Q2 2017 Earnings

Healthcare Biotechnology

Income Statement

Revenue

$1M+7.7% YoY

Gross Profit

$00.0% margin

Operating Income

-$7M-454.4% margin

Net Income

-$7M-448.4% margin

EPS (Diluted)

$-11.75

QoQ Revenue Growth

+50.6%

Cash Flow

Operating Cash Flow

-$6M

Free Cash Flow

-$6M

Stock-Based Comp.

$665,000

Balance Sheet

Total Assets

$67M

Total Liabilities

$5M

Stockholders' Equity

$63M

Cash & Equivalents

$27M

Year-over-Year Comparison

Metric	Current	Year Ago	Change
Revenue	$1M	$1M	+7.7%
Gross Profit	$0	$0	—
Operating Income	-$7M	-$5M	-22.3%
Net Income	-$7M	-$5M	-22.1%